| Previous Close | 81.33 |
| Open | 82.94 |
| Bid | 87.07 x 1000 |
| Ask | 87.25 x 1400 |
| Day's Range | 80.50 - 87.82 |
| 52 Week Range | 3.54 - 189.40 |
| Volume | 1,895,332 |
| Avg. Volume | 5,782,716 |
| Market Cap | 5.38B |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.40 |
| Earnings Date | Aug. 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 220.80 |
- Zacks
Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Novavax Sells 60 Million Doses of Its Coronavirus Vaccine to the U.K. Government
In a Securities and Exchange Commission filing on Wednesday, Novavax (NASDAQ: NVAX) disclosed that the U.K. government had agreed to purchase 60 million doses of NVX-CoV2372, its COVID-19 vaccine candidate. The deal also gives the U.K. the option to make additional orders "from time to time." As part of the agreement, Novavax agreed to create a dedicated supply chain in the U.K. for the production of that country's order.
- Zacks
Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?
During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
